Sandy Cove Advisors LLC Sells 73 Shares of Johnson & Johnson (NYSE:JNJ)

Sandy Cove Advisors LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 1.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,359 shares of the company’s stock after selling 73 shares during the quarter. Sandy Cove Advisors LLC’s holdings in Johnson & Johnson were worth $840,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of JNJ. FIDELIS iM LLC boosted its holdings in shares of Johnson & Johnson by 3.1% in the 4th quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after buying an additional 64 shares during the last quarter. Clearview Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock worth $685,000 after buying an additional 64 shares during the last quarter. TFG Advisers LLC boosted its holdings in shares of Johnson & Johnson by 0.4% in the 3rd quarter. TFG Advisers LLC now owns 18,330 shares of the company’s stock worth $2,855,000 after buying an additional 67 shares during the last quarter. My Legacy Advisors LLC boosted its holdings in shares of Johnson & Johnson by 3.1% in the 4th quarter. My Legacy Advisors LLC now owns 2,222 shares of the company’s stock worth $358,000 after buying an additional 67 shares during the last quarter. Finally, Kellett Wealth Advisors LLC raised its stake in Johnson & Johnson by 3.8% in the 3rd quarter. Kellett Wealth Advisors LLC now owns 1,880 shares of the company’s stock valued at $293,000 after acquiring an additional 68 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $157.96 on Thursday. The firm has a market cap of $380.65 billion, a PE ratio of 11.44, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The business has a 50 day moving average price of $158.76 and a 200-day moving average price of $156.69.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. During the same quarter last year, the firm posted $2.35 earnings per share. The firm’s revenue was down 9.7% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th were issued a $1.19 dividend. The ex-dividend date was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on JNJ. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Morgan Stanley lowered their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, March 13th. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the company from $167.00 to $180.00 in a research report on Friday, December 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.31.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.